Mu Variant Used to Make COVID Vaccines

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant (B.1.621, B.1.621.1) has been tagged as a Variant Being Monitored (VBM), and as of August 30, 2021, it had been detected in 39 countries.

Colombia was identified as the epicenter of SARS-CoV-2 infection caused by the Mu variant. A huge surge of COVID-19 cases was reported in Columbia between March and July 2021, and SARS-CoV-2  infections caused by the gamma variant were found to be prevalent during the early stages of the surge. However, by May, the infections due to the Mu variant became dominant in Columbia.

Reports from WHO suggest that the Mu variant bears mutations that increase the risk of resistance to currently available vaccines and that further investigations are required in this area. The Mu variant is still not considered as a variant of concern by WHO.

Emerging variants of SARS-CoV-2 are concerning. They need to be monitored carefully as they show increased transmissibility, pathogenicity, and have a high risk of resistance to the immune response compared to the original strains.

The scientists in the present study have shown that the Mu variant is resistant to neutralizing antibodies in the sera of COVID-19 convalescents and vaccinated individuals. Further, the sera from Mu-infected individuals showed broad-spectrum antiviral activity.

The sequence of the Mu variant can be utilized to develop vaccines that exhibit broad-spectrum antiviral activity against the original SARS-CoV-2 strain and its variants.

Further, research in this area is required to generate Mu variant-based novel vaccine candidates that can provide effective prophylactic therapy for COVID-19.

Source: https://www.tridhascholars.org/press-release/Mu-variant-used-to-make-covid-vaccines.php

Follow us at Linkedin: https://www.linkedin.com/company/tridha-scholars

Comments

Post a Comment

Popular posts from this blog

COVID- 19 Observation for Fully Vaccinated and Boosted Patients

The researchers concluded that booster doses provided protection against severe COVID-19 symptoms and also observed that the number of patients requiring   mechanical ventilation   and use of vasopressors, as well as in-hospital mortality, were lower in the FV&B cohorts as compared to the UV cohorts, despite a higher risk for in-hospital mortality in the FV&B cohort. When the researchers compared the FV&B patients who required ICU care to those who did not, it was observed that there may not have been enough time for the booster dose in these patients to be effective in preventing COVID-19 symptoms. Decreased in-hospital mortality was observed in FV&B patients compared to UV patients, even though the former group was older and had a higher rate of pre-existing ESRD, higher proportion of immunocompromised state, and a higher proportion of immunocompromised state risk of in-hospital death in the FV&B cohort. It was observed that even among elderly patients with signi
Read more

SARS-CoV-2 Infection and Nasopharyngeal Microbiota

C anadian researchers investigated how  severe acute respiratory syndrome coronavirus 2  (SARS-CoV-2) infection altered the microbiota composition of the host’s nasopharyngeal region. The risk and clinical outcomes of SARS-CoV-2 infection vary widely among individuals. However, the mechanisms underlying these differences in  coronavirus disease 2019  (COVID-19) progression and pathogenesis remain unclear. Studies have shown that the mucosal microbiome influences host toll-like receptor (TLR) expression, which is involved in virus detection. Studies have also shown the prevalence of bacterial co-infections in COVID-19 patients at 6.9%. Likewise, elevated nasal cytokines have been implicated in adverse clinical outcomes in influenza patients. Therefore, exploring upper respiratory tract microbiota compositional changes following SARS-CoV-2 infection could help evaluate its impact on  infection  severity. Overall, the study results presented a granular picture of the microbiota difference
Read more

TRIDHA Scholars : An Open Access Publisher

 HI... TRIDHA Scholars is an open access Publishing company of India and it publishes all kind of paper related to clinical and medical field of Science. We have around 10 running journals on the very kind of particular topic of Clinical Science. Here is the list of the journals below. 1. Journal of Clinical Cases and Report 2. International Journal of Clinical and Medical Informatics 3. Clinical Surgery Journal 4. Cancer Medicine Journal 5. Journal of Medicine and Biology 6. Clinical Practice and Investigation 7. Journal of Heart 8. Case Reports in Dental Science 9. Food Processing and Nutrional Science 10. International Journal of AAYUSH and Traditional Medicine (Official Journal of  SGM, Ayurveda Mahavidyalaya, Pusad, Pune, India ) So, we would like to share it and help us to contribute in scientific community by publishing their work on time. We assure the quality process and complete the peer review process without any fail. Web: https://www.tridhascholars.org/ Contact: contact.tr
Read more